ITM Isotope Technologies Munich and Canadian Nuclear Laboratories have launched a company called Actineer to focus on the production of actinium-225 (Ac-225).
Ac-225 is a radioisotope used in the treatment of cancer. Under terms of the deal, Actineer will establish short-term production capabilities of the isotope based on current infrastructure, with plans being made for the construction of a new production facility.
The joint venture remains subject to further closing conditions expected to be satisfied in early 2024, ITM noted. Canadian Nuclear Labs manages and operates a national laboratory at Chalk River, Ontario, on behalf of Atomic Energy of Canada Limited.